Lead Applied Scientist, Document Understanding This position is based in either Zug, Switzerland or London, UK. Want to use your experience of building document understanding AI solutions to enhance our leading products in the tax, legal and professional
Are you a LaTeX expert fluent in French eager to shape the future of AI? Large‑scale language models are evolving from clever chatbots into powerful engines of scientific discovery. With high‑quality training data, tomorrow’s AI can
Max Planck Institute for Evolutionary Anthropology Postdoctoral position (m/f/d) in One Health surveillance of microbiome transmission at the human-wildlife interface (Leipzig, Germany) The Project and Setting The Tana River region in Kenya is home to agrarian,
Senior Applied Scientist, Search - NLP/GenAI This position is based in either Zug, Switzerland or London, UK. Want to use your experience of building search-led AI solutions to enhance our leading products in the tax, legal
Lead Applied Scientist, Search - NLP/GenAI This position is based in either Zug, Switzerland or London, UK. Want to use your experience of building search-led AI solutions to enhance our leading products in the tax, legal
On behalf of our client, a younger, international, growing business law firm with 500+ lawyers worldwide and a planned presence in Lugano that is likely to expand into other Swiss cities soon, we are looking for
About TetraScience TetraScience is the Scientific Data and AI Company building Tetra OS, the operating system for scientific intelligence. We help the world’s leading life sciences firms turn fragmented scientific data into AI-native assets and scientific
The University of Lucerne is a modern, personal and dynamic human sciences university at the heart of Switzerland and Europe. In keeping with our guiding principle Moving Human Sciences, we focus on people and their institutions
Your team Pictet Alternative Advisors (PAA) is a leading alternative investment group and a wholly owned subsidiary of Pictet with expertise in hedge funds, private equity, real estate and private debt. With teams based globally, PAA
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)